Internal Reference Number: FOI_7170
Date Request Received: 10/05/2023 00:00:00
Date Request Replied To: 16/05/2023 00:00:00
This response was sent via: By Email
Request Summary: intra-vitreal injections or implants
Request Category: Companies
Question Number 1: 1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from January to April 2023: • Aflibercept • Bevacizumab • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis • Ranibizumab – Ongavia • Ranibizumab – Byooviz • Ranibizumab - Ximluci | |
Answer To Question 1: Aflibercept 1350 Bevacizumab 8 Brolucizumab 0 Dexamethasone 10 Faricimab 634 Fluocinolone acetonide 0 Ranibizumab - Lucentis 11 Ranibizumab - Ongavia 0 Ranibizumab - Byooviz 0 Ranibizumab - Ximluci 0 | |
Question Number 2: Please see attached form | |
Answer To Question 2: See attached spreadsheet. To accompany this answer to question 2 please also see the documents listed below: 7170 FOI Q2 answers.xlsx | |
Please see Attachments: | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.